Elacridar in a concentration of 0.5 μM was also capable of decreasing the drug resistance of the BCRP-overexpressing KYN-2 (human pleomorphic HCC) cell line, increasing sensitivity to CPT-11 and SN-38 drugs, as well as in Lovo (human colorectal cancer) and H23 (human adenocarcinoma) cell lines that express high amounts of BCRP mRNA [77]. This evidence concerns the gene ABCG2 and colorectal cancer.